Shaping the future of science

THERAPEUTICS INNOVATION SUMMIT



The forum for scientific excellence and therapeutic innovations of tomorrow



EXCLUSIVE EVENT

Organized by Servier Group, a major player in Oncology, this "by invitation only" event will be held on **June 18, 2024** at the new Servier Paris-Saclay R&D Institute in France.

PANEL OF LEADING INTERNATIONAL SCIENTIFIC EXPERTS

The half-day event will feature leading international scientific experts, under the patronage of **Prof. William G. Kaelin Jr**, Professor of Medicine at Harvard University and recipient of the 2019 Nobel Prize in Medicine.

CATALYST FOR SCIENTIFIC EXCELLENCE

The event will bring together **200 scientific experts**, decision-makers, and healthcare professionals to share their thoughts on therapeutic innovation, its impact on society, and the emergence of new developments expected to accelerate therapeutic research.

An international scientific summit to collectively reflect on major therapeutic advances in oncology

JUNE 18TH, 2024 - FROM 2.00PM TO 6.00PM - AT SERVIER PARIS-SACLAY R&D INSTITUTE

1:30-2:00: WELCOME COFFEE - REGISTRATION

2:00-2:45: OPENING KEYNOTE BY **PROFESSOR WILLIAM G. KAELIN JR**, **2019 NOBEL LAUREATE IN PHYSIOLOGY AND MEDICINE**

2:45-4:00: **A FIRST SESSION** with leading international experts in oncology to discuss on how therapeutic innovation provides solutions to cancer patients with:

- Hsin-An Hou, Hematologist at National Taiwan University Hospital
- Susan Pandya, Vice President Clinical Development, Global Head of Cancer Metabolism at Servier
- Hans Scheurer, PhD, CEO at Myeloma Patients Europe and Vice-chair at European Cancer Patient Advocacy Networks
- Ines Vaz-Luis, MD, Medical oncologist at Gustave Roussy and instructor in Medicine at Harvard University
- **Andrew Wei**, MBBS, PhD, co-leads the acute myeloid leukemia program at the Peter MacCallum Cancer Center and Royal Melbourne Hospital in Melbourne, Australia

4:00-4:30: **COFFEE BREAK**

4:30-5:30: **A SECOND SESSION** with high profile speakers to discuss on how society copes with breakthrough therapeutic innovation with:


- Sandrine Bourguignon, Professor health economist at Paris Dauphine-PSL & RWEality co-founder & CEO
- David Edwards, PhD, Harvard University, Associate in Bioengineering and founder of the World Frontiers Forum think tank
- **Dipak Kalra**, MB BS, President of the European Institute for Innovation Through Health Data
- **Hugues de Thé**, MD, PhD, Professor at the Collège de France, holder of the Chair in Cellular and Molecular Oncology, member of the Academy of Science

Panels moderated by **Ariane Warlin**

5:30-6:00: FIRESIDE CHAT, A WRAP-UP DISCUSSION between Prof. William G. Kaelin and a member of the Servier post-doctoral community.

Possibility to visit the research facilities and to network with guests and speakers

LOCATION OF THE EVENT: Servier R&D Institute at Paris-Saclay: 22, route 128 - 91190 Gif sur Yvette - FRANCE





Servier, founded to serve health and patients









SERVIER IS COMMITTED TO THERAPEUTIC PROGRESS TO SERVE PATIENT NEEDS

- An independent Group, governed by a foundation
- A world leader in cardiometabolic and venous diseases
- An industry innovator in oncology, neuroscience, and immuno-inflammation

SIGNIFICANT SOCIAL IMPACT FOR PATIENTS


- Over **20% of the Group's revenue** from brand-name medicines is invested each year in R&D, **70% of which is dedicated to oncology**
- A promising pipeline of 62 projects, including 36 in development and 26 in research* (half of which are in oncology)

GLOBAL REACH, WITH STRONG HISTORICAL ROOTS IN FRANCE

- **4.9 billion euros** in revenues (2021-2022)
- 2nd leading pharmaceutical group in France
- 97% of active ingredients for the Group's brand-name medicines produced in France
- **59% of Group investments** made in **France**
- More than 70 scientific partnerships and collaborations worldwide
- 4 R&D centers worldwide


(Paris-Saclay - France, Boston - USA, Budapest - Hungary, Ballerup - Denmark)

- **15 offices** worldwide to coordinate clinical development





Scientific excellence at the heart of the Paris-Saclay global innovation hub



PARIS-SACLAY, A WORLD-CLASS RESEARCH AND DEVELOPMENT HUB

concentrating 15% of French R&D.

EXCEPTIONAL ENVIRONMENT

Designed to foster the exchange and sharing of know-how, this exceptional setting provides the ideal conditions for shaping the **innovations of tomorrow**.



UNIQUE ECOSYSTEM

One of the world's top eight innovation clusters,

Paris-Saclay is ideally poised to forge new partnerships and collaborations with institutional and private research stakeholders such as *CNRS*, *CEA*, *École Polytechnique*, the Faculty of Pharmacy, and the University of Paris-Saclay, which is listed in Shanghai Academic Ranking 2023's Top 20¹.

ACCOUNTS FOR 15% OF FRENCH R&D

AMONG TOP 8 INNOVATION HUBS WORLDWIDE

